ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Reamberin

Also written as “Meglumine Sodium Succinate”.

Its studies are mostly in Diabetic Ketoacidosis · Acidosis, led by POLYSAN Scientific & Technological Pharmaceutical.

Furthest: phase 3, since Apr 24, 20252 company-led studies, 1 open or runningNext primary completion: Dec 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
POLYSAN Scientific & Technological Pharmaceutical21 open or runningphase 3since Apr 24, 2025Oct 22, 2021Dec 1, 2027phase 3 · NCT06955416

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 22, 2021First study: phase 2 study in AcidosisFirst studyNCT05147051 · 140 enrolled · Russian Federation
  2. Apr 24, 2025Phase 3 study in Diabetic KetoacidosisNCT06955416 · 312 planned · Russia

Ahead

  1. Dec 1, 2027Primary completion: phase 3 study in Diabetic KetoacidosisNCT06955416

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06955416Diabetic Ketoacidosis · Russia3RecruitingDec 1, 2027312
NCT05147051Acidosis · Russian Federation2CompletedMay 23, 2022140

How it is read

Names in the registry

  • “Reamberin”, 1 entry
  • “Meglumine Sodium Succinate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.